Skip to main content
  • Rivaroxaban Plus Aspirin Reduces Adverse Events After Revascularization in Lower-Extremity PAD Patients

    A twice-daily regimen of 2.5 mg of rivaroxaban plus aspirin significantly reduced lower limb and cardiovascular adverse events in comparison with placebo in patients who underwent revascularization for lower-extremity peripheral artery disease (PAD), according to late-breaking trial results presented Saturday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details